EGFR and hepatocellular carcinoma: Our network pharmacology and MD analysis results indicated that EGFR was involved in the anti-proliferation activity of dihydrotanshinone I against HCC cells, and dihydrotanshinone I may target the allosteric binding pockets of EGFR.